Publication | Closed Access

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Breast OncologyCancer ImmunosurveillanceMedicineImmunologyPathologyImmune Checkpoint InhibitorTumor Infiltrating LymphocytesBreast CancerTrastuzumab BenefitImmunotherapyOncologyTumor MicroenvironmentFinher Trial